Ryvu Therapeutics Signs Cooperation, Licence And Investment Deal With BioNTech
Ryvu Therapeutics SA RVU:
SIGNS RESEARCH COOPERATION DEAL, EXCLUSIVE LICENCE DEAL AND INVESTMENT DEAL WITH BIONTECH
PARTIES TO DEVELOP SMALL MOLECULE COMPOUNDS FOR THERAPY FOCUSED MAINLY ON IMMUNOLOGICAL MODULATION IN ONCOLOGY
REMUNERATION AT EUR 20.0 MILLION FOR GLOBAL, EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE A PORTFOLIO OF STAND-ALONE SMALL-MOLECULE STING AGONISTS
REMUNERATION ALSO FOR RIGHT TO OBTAIN EXCLUSIVE LICENSE FOR SEVERAL PROGRAMS WITHIN FRAMEWORK OF RESEARCH COOPERATION COVERING MANY THERAPEUTIC PURPOSES
ACCORDING TO LICENSE AGREEMENT, BIONTECH WILL FINANCE ALL RESEARCH AND DEVELOPMENT COSTS AS PART OF COOPERATION
COMPANY WILL BE ENTITLED TO GET PAYMENT OF UP TO EUR 876.2 MILLION FOR POTENTIAL MILESTONES
AMOUNT OF UP TO EUR 876.2 MILLION IS BIO-EURO VALUE
UNDER INVESTMENT AGREEMENT, BIONTECH TO INVEST FURTHER EUR 20.0 MILLION BY ACQUISITION OF NEW J-SERIES SHARES
BIONTECH TO HAVE PRIORITY RIGHT FOR NEGOTIATIONS ON ANY OF COMPANY'S ONCOLOGICAL MODULATION PROJECTS BEYOND SCOPE OF PARTNERSHIP DEAL
PRIORITY RIGHT TO RUN FOR FIVE YEARS FROM LICENCE DEAL OR TILL SELECTION OF BIONTECH EXCLUSIVE THERAPEUTIC GOALS
INITIAL PERIOD OF COOPERATION IS FIVE YEARS AND MAY BE EXTENDED